Our research effort is focused on the design and synthesis of novel ligands to study the function of selected CNS receptors and monoamine transporters. Highly selective compounds are designed for characterization of structure-activity relationships at these molecular targets. In addition, specific tools are synthesized such as irreversible, radiolabeled and/or fluorescent ligands for receptor topological mapping studies and the elucidation of pharmacological function. Our primary focus is toward elucidating mechanisms underlying addiction through the design, synthesis and pharmacological evaluation of novel dopamine uptake inhibitors and dopamine receptor subtype-selective ligands. In addition, we are synthesizing novel allosteric modulators of the mGluR5 receptor and the serotonin transporter.

I did my M.Sc form Indian Institute of Technology and PhD from Indian association for the cultivation of science. After finishing my 1st post doc at Kent State Univeristy I am doing my 2nd post doc at NIDDk, NIH, LBC, under the supervision of Dr. Kenneth A. Jacobson

Postdoctoral Fellow in Dr. Dan Appella's Lab in the NIDDK. Graduated from Univ. of Delaware Spring 2007 from Dr. Joel P. Schneider's lab after working with self-assembling beta-hairpin peptides.

I'm helping to create the Chemistry SIG site and will remove myself once this is up and running.

Dr. Cynthia Dowd has a BA in Chemistry from the University of Virginia (1993) and a PhD in Medicinal Chemistry from Virginia Commonwealth University (1999). After a postdoc at the University of Pennsylvania, Dr. Dowd worked on the design and synthesis of antitubercular drugs at NIAID/NIH. In 2007, she joined the Chemistry Department faculty at George Washington University where her research focuses on anti-infective drug design.

Senior Investigator.

Technical Laboratory Manager Laboratory of Medicinal Chemistry

After working for seven years as a research engineer for the DuPont Co. and then, 20 years of being a stay-at-home mother, I am returning to school to obtain a PhD in Organic Chemistry under Dr. Cynthia Dowd at the George Washington University.

Dr. Kenneth A. Jacobson is Acting Chief, Laboratory of Bioorganic Chemistry and Chief, Molecular Recognition Section, NIDDK, NIH in Bethesda, Maryland. He is a medicinal chemist with interests in the structure and pharmacology of G protein-coupled receptors, in particular adenosine and nucleotide receptors. Ph.D. in Chemistry at the University of California, San Diego (1981), Bantrell Fellow at Weizmann Institute of Science. Awarded "Highly Cited Researcher" in Pharmacology and Toxicology, 2003 Hillebrand Prize of the Chemical Society of Washington, and 2009 Pharmacia-ASPET Award in Experimental Therapeutics. Dr. Jacobson has served as Chair of the Medicinal Chemistry Division of the ACS.

Bsc/PhD from the University of Sydney, specializing in bioinorganic chemistry and metal-based therapeutics. Now in LCB working on drug transporters in cancer multidrug resistance and drug development to overcome this phenomenon.

I have pursued my doctorial studies under the supervision of Prof. Jesper Wengel, University of Southern Denmark, where I worked on synthesizing modified nucleic acids and evaluated their potential application in the nucleic acid based therapeutics and diagnostics. Currently, I am working as postdoctorial visiting fellow in Dr. Kenneth Jacobson's lab.

I received my Ph.D. in medicinal chemistry from the University of Washington (Seattle) and currently head the Bioorganic and Medicinal Chemistry Section within the Laboratory of Medicinal Chemistry. My research focuses on the application of peptide and peptide mimetic chemistries to areas of potential therapeutic interest to the NCI.

I joined the Section as a Radiochemist in 2008. I received my B.Sc. (Chemistry, 1990) and M.Sc. (Physical Chemistry, 1993) from Nan Kai University, China. I worked as a Research Associate and Lecturer at the Department of Chemical Engineering, Beijing Institute of Technology in China for three years before obtaining my Ph.D. (Organic Chemistry, 2001) from New Mexico State University, USA. I performed postdoctoral research on developing [18F]radiotracers for studying α4β2 nAChRs in the brain for three years at the National Institute on Drug Abuse (NIDA/NIH). Before joining NIMH, I spent five years working on developing drugs for CNS disorders in the Intramural Research Program at the PET section of NIDA/NIH, followed by two years as a Research Scientist developing opioid ligands within the Drug Design and Synthesis Section, Chemical Biology Research Branch. My current interests focus on producing radiotracers for PET studies, developing new radiosynthetic methods with modified automated apparatus and documentation of radiotracer production according to GMP requirements in support of IND applications.